Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics — COVID-19 Testing Sales ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2024
725
Period ended Dec 31, 2024
Change on a year earlier
-52.4%
1,523 in FY2023
History
3 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics — COVID-19 Testing Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 725 | -52.4% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 1,523 | -80.7% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 7,895 | – | SEC Filing (0001628280-24-002009) ↗ |
Breakdown
What makes up rapid diagnostics — covid-19 testing sales ($m)
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics — COVID-19 Testing Sales ($M) ($M), annual FY2022–FY2024 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-covid-rev
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.